Causes of mortality in neurofibromatosis type 2

References

• Martuza RL, Eldridge R. Neurofibromatosis 2 (bilateral acoustic neurofibromatosis). N Engl J Med 1988;318:684–8.
   PubMed Web of Science ®Google Scholar
• Kanter WR, Eldridge R, Fabricant R, Allen JC, Koerber T. Central neurofibromatosis with bilateral acoustic neuroma: genetic, clinical and biochemical distinctions from peripheral neurofibromatosis. Neurology 1980;30:851–9.
   PubMedGoogle Scholar
• Evans DG, Huson SM, Donnai D, et al. A clinical study of type 2 neurofibromatosis. J Med Genet 1992;84:603–18.
   Google Scholar
• Parry DM, Eldridge R, Kaiser-Kupfer MI, et al. Neurofibromatosis 2 (NF2): clinical characteristics of 63 affected individuals and clinical evidence for heterogeneity. Am J Med Genet 1994;52: 450–61.
   PubMed Web of Science ®Google Scholar
• Parry DM, MacCollin MM, Kaiser-Kupfer MI, et al. Germ-line mutations in the neurofibromatosis 2 gene: correlations with disease severity and retinal abnormalities. Am J Hum Genet 1996;59:529–39.
   PubMed Web of Science ®Google Scholar
• Ruttledge MH, Andermann AA, Phelan CM, et al. Type of mutation in the neurofibromatosis type 2 gene (NF2) frequently determines severity of disease. Am J Hum Genet 1996;59:331–42.
   PubMed Web of Science ®Google Scholar
• Selvanathan SK, Shenton A, Ferner R, et al. Further genotype–phenotype correlations in neurofibromatosis 2. Clin Genet 2010;77:163–70.
   PubMedGoogle Scholar
• Baser ME, Friedman JM, Aeschliman D, et al. Predictors of the risk of mortality in neurofibromatosis 2. Am J Hum Genet 2002;71:715–23.
   PubMed Web of Science ®Google Scholar
• Goutagny S, Bah AB, Parfait B, Sterkers O, Kalamarides M. Neurofibromatosis type 2 in the elderly population: clinical and molecular features. Am J Med Genet A 2013;161:667–70.
   Google Scholar
• Aboukais R, Baroncini M, Zairi F, et al. Prognostic value and management of spinal tumors in neurofibromatosis type 2 patients. Acta Neurochir (Wien) 2013;155:771–7.
   PubMed Web of Science ®Google Scholar
• Dow G, Biggs N, Evans G, et al. Spinal tumors in neurofibromatosis type 2. Is emerging knowledge of genotype predictive of natural history? J Neurosurg Spine 2005;2:574–9.
   Google Scholar
• Steele CM. The physiology of deglutition and the pathophysiology and complications of oropharyngeal dysphagia. Nestle Nutr Inst Workshop Ser 2012;72:13–7.
   Google Scholar
• Tees D, Lofchy N, Rutka J. Deafness, dysphagia and a middle ear mass in a patient with neurofibromatosis type 2. J Otolaryngol 1992;21:227–9.
   PubMedGoogle Scholar
• Fisher LM, Doherty JK, Lev MH, Slattery WH III. Distribution of nonvestibular cranial nerve schwannomas in neurofibromatosis 2. Otol Neurotol 2007;28:1083–90.
   Google Scholar
• Kaspar K, Ekberg O. Identifying vulnerable patients: role of the EAT-10 and the multidisciplinary team for early intervention and comprehensive dysphagia care. Nestle Nutr Inst Workshop Ser 2012;72:19–31.
   PubMedGoogle Scholar
• Oyama H, Kito A, Maki H, et al. Schwannoma originating from lower cranial nerves: report of 4 cases. Nagoya J Med Sci 2012;74:199–206.
   Google Scholar
• Pollock BE, Foote RL, Stafford SL. Stereotactic radiosurgery: the preferred management for patients with nonvestibular schwannomas? Int J Radiat Oncol Biol Phys 2002;52:1002–7.
   PubMed Web of Science ®Google Scholar
• Evans DG, Birch JM, Ramsden RT, Sharif S, Baser ME. Malignant transformation and new primary tumours after therapeutic radiation for benign disease: substantial risks in certain tumour prone syndromes. J Med Genet. 2006;43:289–94.
   PubMed Web of Science ®Google Scholar
• Plotkin SR, Merker VL, Halpin C, et al. Bevacizumab for progressive vestibular schwannoma in neurofibromatosis type 2: a retrospective review of 31 patients. Otol Neurotol 2012;33:1046–52.
   PubMed Web of Science ®Google Scholar
• Letarte N, Bressler LR, Villano JL. Bevacizumab and central nervous system (CNS) hemorrhage. Cancer Chemother Pharmacol 2013;71:1561–5.
   PubMedGoogle Scholar
• Nunes FP, Merker VL, Jennings D, et al. Bevacizumab treatment for meningiomas in NF2: a retrospective analysis of 15 patients. PLoS One 2013;8:e59941.
   PubMed Web of Science ®Google Scholar
• Wieseke A, Bantz D, Siktberg L, Dillard N. Assessment and early diagnosis of dysphagia. Geriatr Nurs 2008;29:376–83.
   PubMed Web of Science ®Google Scholar
• Olszewski J. [Causes, diagnosis and treatment of neurogenic dysphagia as an interdisciplinary clinical problem]. Otolaryngol Pol 2006;60:491–500.
   Google Scholar
• Aboukais R, Zairi F, Baroncini M, et al. Intracranial meningiomas and neurofibromatosis type 2. Acta Neurochir (Wien) 2013;155: 997–1001.
   Google Scholar
• Rose DS, Fisher C, Smith ME. Epithelioid sarcoma arising in a patient with neurofibromatosis type 2. Histopathology 1994;25: 379–80.
   Google Scholar
• Baser ME, De Rienzo A, Altomare D, et al. Neurofibromatosis 2 and malignant mesothelioma. Neurology 2002;59:290–1.
   PubMed Web of Science ®Google Scholar
• Nemoto H, Tate G, Kishimoto K, et al. Heterozygous loss of NF2 is an early molecular alteration in well-differentiated papillary mesothelioma of the peritoneum. Cancer Genet 2012; 205:594–8.
   Google Scholar
• Evans DG, Huson SM, Birch JM. Malignant peripheral nerve sheath tumours in inherited disease. Clin Sarcoma Res 2012;2:17.
   PubMedGoogle Scholar
• Neary WJ, Hillier VF, Flute T, et al. The relationship between patients’ perception of the effects of neurofibromatosis type 2 and the domains of the Short Form-36. Clin Otolaryngol 2010;35:291–9.
   Google Scholar
• Neary WJ, Hillier VF, Flute T, et al. Use of a closed set questionnaire to measure primary and secondary effects of neurofibromatosis type 2. J Laryngol Otol 2010;124:720–8.
   PubMedGoogle Scholar
• Vitucci JB. Importance of local support groups for acoustic neuroma and neurofibromatosis patients. Otolaryngol Clin North Am 2012;45:531–5.
   PubMed Web of Science ®Google Scholar
• Belzeaux R, Lancon C. [Neurofibromatosis type 1: psychiatric disorders and quality of life impairment]. Presse Med 2006;35: 277–80.
   Google Scholar
• Harris C. Neurofibromatosis type 2-living with the complications: a case study. J Neurosci Nurs 2005;37:156–8.
   Google Scholar
• Patel CM, Ferner R, Grunfeld EA. A qualitative study of the impact of living with neurofibromatosis type 2. Psychol Health Med 2011;16:19–28.
   PubMed Web of Science ®Google Scholar